Product Pipeline
11/17/1999 Data on Corixa's AnergiX.RA complex presented at American College of Rheumatology Conference
Interim analysis provides evidence of safety and clinical activity
11/04/1999 Corixa receives Canadian regulatory approval for its Melacine melanoma therapeutic vaccine
Corixa’s Melacine becomes the first commercially-available, therapeutic cancer vaccine
10/27/1999 Allergy Therapeutics LTD presents data on use of Corixa's MPL adjuvant in newly launched Pollinex Quattro allergy vaccines
Corixa’s MPL adjuvant launched in Germany for patient-specific use
10/26/1999 Corixa reports strong third quarter results
Revenue for third quarter increased 328 percent compared to prior year period
10/07/1999 Corixa Corporation completes acquisition of Ribi ImmunoChem Research, Inc.
09/24/1999 Shareholders approve Corixa's acquisition of Ribi ImmunoChem Research, Inc.
08/19/1999 Corixa and Zenyaku Kogyo form collaboration to develop and distribute psoriasis product, PVAC, in Japan
08/17/1999 Corixa CSO presents mammaglobin data at IBC Conference on Immunotherapy for Cancer
Steven Reed, Ph.D., discusses effectiveness of mammaglobin in detecting breast cancer
07/26/1999 Corixa reports second quarter results
Revenue for second quarter up 94 percent from first quarter
06/30/1999 Corixa CEO, Steven Gillis, Ph.D., named Ernst & Young entrepreneur of the year in healthcare
06/16/1999 Corixa partners with Japan Tobacco to research lung cancer vaccines in Japan and North America
06/10/1999 Corixa to acquire Ribi ImmunoChem Research, Inc.
Agreement extends Corixa’s product portfolio and vaccine technologies
05/26/1999 Corixa appoints Cindy Jacobs, M.D., Ph.D., as Vice President and Director of Clinical Research
Cindy Jacobs joins Corixa to swiftly lead products through clinical trials
05/24/1999 Zambon and Corixa team up to fight lung cancer
License rights aimed at European market
04/26/1999 Corixa reports first quarter results
04/09/1999 Corixa Corporation obtains $50 million financing
Funds intended to strengthen consolidation growth strategy
04/06/1999 Corixa releases interim Phase I clinical trial results for its novel vaccine adjuvant, LeIF
LeIF-enhanced T cell vaccine produces improvement in 67 percent of patients
03/31/1999 Corixa and the Infectious Disease Research Institute announce $12 million ex vivo collaboration
Partnership will fund research and development for adoptive immunotherapy
03/15/1999 Corixa announces senior management promotions
03/15/1999 Corixa receives U.S. patents on vaccine adjuvant, LeIF
Protein may enhance multiple cancer and infectious disease vaccines
03/15/1999 Corixa announces U.S. patent issuance on cancer-related protein, Her-2/neu
Patent is licensed to Corixa on exclusive worldwide basis
02/22/1999 Corixa initiates Phase I trial for Microsphere-encapsulated cancer vaccine
02/17/1999 Corixa reports fourth quarter and year end results
175 percent fourth quarter revenue gain driven by partnering agreement
02/12/1999 Corixa completes acquisition of Anergen, Inc.
Company adds additional therapies for prevention and treatment of autoimmune diseases
02/01/1999 Corixa announces U.S. patent issuance on breast cancer protein, mammaglobin
Patent is licensed to Corixa on exclusive worldwide basis
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Current and archived company press releases.